MedTrace Logo

18F-FDOPA PET in Neuroendocrine Tumours

NCT02431715 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2023-02-21

No results posted yet for this study

Summary

Neuroendocrine tumours (NETs) are a group of neoplasms generally arising from the gastroenteropancreatic tract. They are usually slow growing, have low malignant potential, and often go unnoticed until they become metastatic. The correct treatment approach is dependent on the extent of the disease, however surgical approaches and systemic therapy can be curative.

Combined positron emission tomography/computed tomography (PET/CT) using the radiotracer 18F-6-L-fluorodihydroxyphenylalanine (18F-FDOPA) has been shown to be a promising non-invasive technique to help localizing NETs and guide their treatment.

Conditions

  • Thyroid Cancer, Medullary
  • Carcinoid Tumor
  • Pheochromocytoma
  • Paraganglioma
  • Insulinoma
  • Neuroblastoma

Interventions

DRUG

[18 F]-6-L-fluorodihydroxyphenylalanine (18F-FDOPA)

All patients will have their weight and baseline vital signs recorded. The study subject will have an intravenous catheter inserted and receive a slow bolus intravenous dose of 185 - 370 MBq (5 -10mCi) 18F-FDOPA. The patient will rest in a comfortable reclining chair in a warm, private shielded room for 45 to 60 minutes. Patients are positioned supine and centered on the scanner bed for an average total scan time (CT and PET) of approximately 30 minutes. Images will be interpreted by qualified and experienced physicians. Findings of significance from the PET/CT scan, and any incidental findings of significance from the CT scan, will be included in the single final report that will be issued to referring physicians.

Sponsors & Collaborators

  • British Columbia Cancer Agency

    lead OTHER

Eligibility

Min Age
1 Month
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02431715 on ClinicalTrials.gov